Allelodrene was initially developed by Pharmacon?
as one of a raft of cheap fertility treatments in response to the declining population levels of the time. However, research was abandoned during the late stage of animal testing, when it was found to induce an unacceptably high proportion of heavy (and usually fatal) embryo mutations.
Despite this, identifiable samples of Allelodrene began to appear on the black market almost immediately, branded as generic fertility drugs. By the time of the [Qirel Encounter]?, Allelodrene had been in widespread public use for almost a year, and multiple births were becoming increasingly common.